Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 1301 - 1350 of 3753 results
- Specific targeting of pancreatic islet cells in vivo by insulin-promoter-driven adenoviral conjugated reporter genes.
- Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1.
- Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor.
- Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
- Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.
- Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins.
- Generation of insulin-secreting cells from pancreatic acinar cells of animal models of type 1 diabetes.
- A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
- IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
- A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.
- Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects.
- Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
- Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.
- Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.
- 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
- Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
- Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
- Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes.
- Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.
- The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction.
- Resistin worsens cardiac ischaemia-reperfusion injury.
- Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile.
- Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.
- The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist.
- Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients.
- New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study.
- Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy.
- Sirolimus is associated with reduced islet engraftment and impaired beta-cell function.
- Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
- Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice.
- Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes.
- Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study.
- Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment.
- Intranasal insulin improves memory in humans: superiority of insulin aspart.
- Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus.
- Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).
- Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
- PDE5 inhibitors in diabetic peripheral neuropathy.
- Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes.
- A case series: evaluation of the metabolic safety of aripiprazole.
- Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction.
- Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors of glycogen phosphorylase a.
- Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
- Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
- High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
- Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
- Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
- A novel oxazine ring closure reaction affording (Z)-((E)-2-styrylbenzo[b]furo[3,2-d][1,3]oxazin-4-ylideno)acetaldehydes and their anti-osteoclastic bone resorption activity.
- Insulin resistance and impaired beta cell function in rheumatoid arthritis.
- Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >